CCA
KRYS icon

Catalyst Capital Advisors’s Krystal Biotech KRYS Stock Holding History

Catalyst Capital Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-465
Closed -$5K – 460
2017
Q3 		$5K Buy
+465
New +$4.69K ﹤0.01% 406

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Catalyst Capital Advisors's KRYS Position: Q4 2017 in Review

Catalyst Capital Advisors sold out of Krystal Biotech (KRYS) in Q4 2017, closing a stake of 465 shares — an estimated $5K sold.

Catalyst Capital Advisors first reported a position in KRYS in Q3 2017 and held it in 1 quarter. The position peaked at $5K in Q3 2017. 13 funds tracked by Wall St. Rank hold KRYS as of Q4 2017.

  • Catalyst Capital Advisors reported no remaining Krystal Biotech position as of Q4 2017 after selling out during the quarter.
  • Catalyst Capital Advisors sold 465 Krystal Biotech shares in Q4 2017, an estimated $5K.
  • Catalyst Capital Advisors first reported a position in Krystal Biotech in Q3 2017 and held it in 1 quarter.
  • Catalyst Capital Advisors's Krystal Biotech position peaked at $5K in Q3 2017.
  • 13 funds tracked by Wall St. Rank held Krystal Biotech as of Q4 2017.

Based on Catalyst Capital Advisors's 13F filing for Q4 2017, filed 8 Feb 2018.